Overview: MICA Antibodies TestIntroduction: The MICA Antibodies Test detects MICA antibodies to assess transplant rejection risk, helping guide immunosuppressive therapy in transplant patients. Affecting 1 in 10 transplant recipients, MICA antibodies pose diagnostic challenges due to immune response variability. Following 2023 American Society of Transplantation (AST) guidelines, it uses ELISA for high accuracy, supporting immunology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in transplantation.
Other Names: MICA Antibody Test, Transplant Rejection Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: MICA antibody testing began in the 2000s with research by Zou, who linked it to rejection. ELISA advancements by Thermo Fisher improved detection, surpassing earlier flow cytometry methods.
Purpose: Detects MICA antibody levels to assess rejection risk, guides immunosuppressive therapy, and evaluates transplant patients, aiming to prevent graft loss.
Test Parameters: MICA antibody levels
Pretest Condition: No special preparation required. Collect serum. Report history of transplantation.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document transplant history. Include current medications or rejection episodes.
Consent: Written consent required, detailing the test's purpose, rejection risks (e.g., graft failure), and sample collection risks.
Procedural Considerations: Uses ELISA to measure antibodies, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest rejection risk, guiding therapy. Early adjustment might prevent loss, while untreated cases lead to graft failure. Normal levels may require monitoring.
Specialist Consultation: Consult a transplant specialist for interpretation.
Additional Supporting Tests: HLA typing, biopsy, or DSA levels to confirm diagnosis.
Test Limitations: Specific to MICA; correlation with clinical status needed. False positives possible with other antibodies.
References: AST Guidelines, 2023; Transplantation, Zou Y, 2022.
